# EDGAR Filing Document

**Accession Number:** 0001580149
**File Stem:** 0001520138-25-000223
**Filing Date:** 2025-7
**Character Count:** 12641
**Document Hash:** 77f025689bf75225db0fb645a43bfe67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001520138-25-000223.hdr.sgml**: 20250723

**ACCESSION NUMBER**: 0001520138-25-000223

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250717

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250723

**DATE AS OF CHANGE**: 20250723

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOVIE INC.
- **CENTRAL INDEX KEY:** 0001580149
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462510769
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39015
- **FILM NUMBER:** 251143658

**BUSINESS ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703
- **BUSINESS PHONE:** 775-888-3162

**MAIL ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOANTIBIOTICS, INC.
- **DATE OF NAME CHANGE:** 20130625

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION** WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **July 17, 2025**

**<u>BioVie Inc.</u>**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | 001-39015 | **46-2510769** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **680 W Nye Lane Suite 201**<br> **Carson City, NV** | **89703** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**<u>(775) 888-3162</u>** (Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, par value $0.0001 per share | BIVI | The NASDAQ Stock Market, LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 17, 2025, the Board of Directors (the "Board") of BioVie Inc. (the "Company") increased the size of the Board from four (4) to six (6) directors and appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to the Board, effective immediately.

There is no arrangement or understanding between either of Dr. Chappell or Mr. Farag and any other person pursuant to which Dr. Chappell and Mr. Farag were selected as directors of the Company, nor are either of Dr. Chappell or Mr. Farag a member of the family of any executive officer of the Company or of any other director of the Company. There have been no transactions, proposed or otherwise, in which either of Dr. Chappell or Mr. Farag participated or will participate that would be required to be disclosed herein pursuant to Item 404(a) of Regulation S-K. Dr. Chappell and Mr. Farag will participate in the compensation program the Company maintains for its non-management directors.

**Item 7.01 Regulation FD Disclosure**

On July 22, 2025, the Company issued a press release announcing the appointment of Dr. Chappell and Mr. Farag to the Board. The press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](bivi-20250722_8kex99z1.htm) | [Press Release, dated July 22, 2025](bivi-20250722_8kex99z1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 23, 2025

---

| | |
|:---|:---|
| **BIOVIE INC.** | **BIOVIE INC.** |
| By: | /s/ Joanne Wendy Kim |
| Name: | Joanne Wendy Kim |
| Title: | Chief Financial Officer |

---

## Exhibit 99.1

![](image_001.jpg)

**BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors**

***Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission***

**Carson City, NV, July 22, 2025** – BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors.

"Amy and Kameel each bring an extraordinary combination of strategic vision, operational excellence, and hands-on experience developing and commercializing therapies in complex neurological and chronic diseases," said Cuong Do, President and Chief Executive Officer (CEO) of BioVie Inc. "As BioVie continues to advance bezisterim through Phase 2 trials for early Parkinson's disease and long COVID, and plans the next steps in clinical development in our Alzheimer's disease and ascites programs, their expertise will be invaluable in achieving our mission of transforming the treatment of these devastating conditions."

Dr. Chappell brings decades of experience in clinical neuroscience and drug development. Over a 25-year career at Eli Lilly & Co., she played a central role in developing and gaining US Food and Drug Administration (FDA) approvals for multiple central nervous system (CNS) indications, including for Cymbalta® in fibromyalgia and musculoskeletal pain. She later served as Chief Medical Officer (CMO) for Eliem Therapeutics, assisting it through a successful initial public offering (IPO) and advancing programs in epilepsy and mood disorders. Currently, as CMO of Solaxa Inc., she oversees clinical development of novel therapies for ataxia and nerve repair. Dr. Chappell holds numerous patents, has authored over 100 peer-reviewed publications and presentations, and remains a Fellow of the American Academy of Neurology.

Mr. Farag is a proven biotech and global finance executive with a track record of scaling companies through transformational growth. Most recently, as Chief Financial Officer (CFO) and head of business operations at Aspen Neuroscience, he oversaw tripling the company's headcount, secured over $150 million in financing, built manufacturing infrastructure, and prepared the company for clinical data and a potential future public offering. He previously served as SVP of Finance at Ionis Pharmaceuticals, and Regional CFO for Amgen's international business, where he helped expand ex-US presence, double regional revenues and build global operational capabilities. His strategic leadership and capital markets expertise will help guide BioVie through its next phase of development.

These appointments come at a time of growing momentum for BioVie. The Company recently <u>published</u> and presented promising data on bezisterim's potential to slow or reverse biological aging and neurodegeneration at the <u>7th World Aging and Rejuvenation Conference</u>. BioVie also recently initiated its <u>ADDRESS-LC</u> Phase 2 long COVID trial and continues to drive patient-focused clinical innovation with the <u>SUNRISE-PD</u> Parkinson's study.

**About BioVie Inc.** 

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit <u>www.bioviepharma.com</u>.

**Forward-Looking Statements** 

*This press release contains forward-looking statements, which may be identi ed by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. 3Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise su cient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports led by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.*

***For Investor Relations Inquiries:*** <br> Chuck Padala<br> Managing Director, LifeSci Advisors, LLC <br> <u>chuck@lifesciadvisors.com</u>

 ****

***For Media Inquiries:***

Melyssa Weible

Managing Partner, Elixir Health Public Relations

<u>mweible@elixirhealthpr.com</u>